Navigation Links
Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting

SAN DIEGO, April 14, 2011 /PRNewswire/ -- New results from the largest multicenter clinical trial for heart transplant patients will be released this week at the International Society for Heart & Lung Transplantation (ISHLT) 31st Annual Meeting and Scientific Sessions in San Diego.  Results show clinical benefit for the use of Everolimus in heart transplant patients.

The trial includes 721 randomized patients at 67 medical centers spanning 5 continents.  The research compared the efficacy of anti-rejection therapy Everolimus with the current standard of care Mycophenolate Mofetil (MMF).

Research to be presented at the ISHLT Meeting includes:

  • Everolimus-Based Immunosuppression Versus Conventional Treatment in Long-Term Heart Transplanted Patients: Three Years Results of a Prospective Randomized Trial (abstract 2) is a featured abstract during the Thursday morning Opening Plenary Session at 9:30am PDT.
  • Reduction of Cardiac Allograft Vasculopathy with Everolimus over Mycophenolate Mofetil: Intravascular Ultrasound Results of a Randomized Multicenter Trial (abstract 52) will be presented Thursday during an afternoon symposium at 2:00pm PDT.
  • Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis (abstract 55) will be discussed during the same Thursday symposium at 2:45pm PDT.
  • Heart Transplant Recipients Treated with Everolimus Have Less Increase in Intimal Thickness vs MMF, Irrespective of Lipid Values (abstract 57), will also be presented on Thursday afternoon, 3:15pm PDT.


Intravascular Ultrasound Results

One study, specifically looking at intravascular ultrasound (IVUS) results, showed a robust benefit with Everolimus relative to Mycophenolate Mofetil (MMF) by IVUS at the end of one year.  This study included 189 patients:  88 patients randomized to Everolimus at low dose of 1.5 mg/day and 101 randomized to MMF. There was no significant difference between the groups with regard to baseline demographics.

"The fact that data was so robust in all IVUS parameters is very significant and clinically applicable" according to the principal investigator Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles.

The data show that a significantly smaller percentage of patients had a change in intimal thickness greater than 0.5mm during the first year after heart transplant in the Everolimus group versus the MMF group. In addition to a benefit in intimal thickness there was also a significant improvement in three dimensional intimal volume in the Everolimus group.  According to Dr. Kobashigawa, this data is crucial, because previous IVUS studies have shown high morbidity and mortality rates at 5 years in those patients with an increase in intimal thickness greater than .5 mm in the first year after heart transplantation.  

On average, all subgroups in the study showed clinical benefit with Everolimus, including patients over 50 years of age, both males and females, diabetics, and patients with previous disease.  

Everolimus with Reduced CsA

These investigators compared Everolimus given with reduced levels of Cyclosporine (CsA) with MMF using standard levels of CsA, specifically looking at the drugs' efficacy and affect on kidney function.

Researchers found that Everolimus does not appear to be superior to MMF in terms of acute cellular rejection, but that adverse effects on the kidneys can be prevented by using lower doses of CsA.  

According to principal investigator, Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, using a lower dose of CsA also showed a significant reduction in transplant coronary disease as described above and less infection with cytomegalovirus (CMV).

In this study, 282 patients received Everolimus at 1.5mg/day dose, 168 received Everolimus at 3mg/day dose and 271 received MMF.  Investigators noted that the 3mg arm was terminated early by the Data Safety Monitoring Board due to higher mortality.

"All immunosuppression drugs are complicated and require experience with these drugs to determine the best way to use them.  This trial has provided enough experience with Everolimus to teach us how to use this medication to help patients.  If Everolimus is combined with a low dose of CsA and we can minimize the use of immunosuppression therapy post transplant, then Everolimus reduces the likelihood of severe complications, like transplant coronary disease and CMV," said Dr. Eisen.

Researchers noted that further study is required to answer additional questions, such as those related to the issue of malignancy.  Other studies suggest a potential beneficial effect with the class of drugs that includes Everolimus in blocking a certain protein leading to malignant growth, but further research is needed to demonstrate real benefit.

Dr. Eisen concluded that this research is very promising.  MMF is a very effective drug, and results showing the same rate of rejection with Everolimus are not surprising.  However, the positive results demonstrating that using less CsA to reduce the likelihood of renal failure with the same incidence of rejection and a reduced incidence of transplant coronary disease and CMV confirm that Everolimus is an effective anti-rejection therapy for heart transplant patients.


The International Society for Heart & Lung Transplantation (ISHLT) is a not-for-profit organization dedicated to the advancement of the science and treatment of end-stage heart and lung diseases.  Created in 1981, the Society now includes more than 2,200 members from 45-plus countries, representing a variety of disciplines involved in the management and treatment of end-stage heart and lung disease. For more information, visit

Contact:  Lauren Daniels
(210) 857-2521

SOURCE International Society for Heart & Lung Transplantation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):